Company intelligence / Profile preview
iRenix Medical, Inc.
Palo Alto, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
iRenix Medical’s lead product candidate IRX–101 is a non-toxic ocular antiseptic designed to reduce post-intravitreal injection pain and corneal epitheliopathy. It has reached Phase III clinical trials with ongoing studies comparing its safety and efficacy against standard povidone–iodine treatment in patients receiving intravitreal anti–VEGF injections. The company also develops an ultra–rapid non-pharmacologic ocular anesthesia device[1][5].
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecule drugsOphthalmic devices (non-pharmacologic ocular anesthesia device)Non-toxic ocular antiseptic for intravitreal injection therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on iRenix Medical, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iRenix Medical, Inc..